[1] |
Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/ idiopathic multicentric Castleman disease[J]. Blood, 2017, 129(12):1646-1657.
doi: 10.1182/blood-2016-10-746933
pmid: 28087540
|
[2] |
中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(07):529-534.
|
[3] |
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multi centric Castleman disease[J]. Blood, 2018, 132(20):2115-2124.
|
[4] |
Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease[J]. Blood, 2018, 132(22):2323-2330.
doi: 10.1182/blood-2018-05-848671
pmid: 30487129
|
[5] |
Fujimoto W, Kanehiro A, Kuwamoto-Hara K, et al. Paraneoplastic pemphigus associated with Castleman’s disease and asymptomatic bronchiolitis obliterans[J]. Eur J Dermatol, 2002, 12(4):355-359.
pmid: 12095881
|
[6] |
Chin AC, Stich D, White FV, et al. Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: a rare case of Castleman’s disease with respiratory failure requiring lung transplantation[J]. J Pediatr Surg, 2001, 36(12):E22.
doi: 10.1053/jpsu.2001.28877
pmid: 11733934
|
[7] |
Wei A, Ma H, Li Z, et al. Successful treatment of a child with idiopathic multicentric Castleman disease associated with hemophagocytic lymphohistiocytosis using tocilizumab[J]. Pediatr Blood Cancer, 2019, 66(7):e27759.
doi: 10.1002/pbc.v66.7
|
[8] |
Zondag TC, Rokx C, van Lom K, et al. Cytokine and viral load kinetics in human herpesvirus associated multicentric Castleman’s disease complicated by hemophagocytic lymphohistiocytosis[J]. J Hematol, 2016, 103(4):469-472.
|
[9] |
Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature[J]. Cancer, 1999; 85(3):706-717.
pmid: 10091744
|
[10] |
Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy[J]. Cancer, 2001, 92(3):670-676.
pmid: 11505414
|
[11] |
Parez N, Bader-Meunier B, Roy CC, et al. Paediatric Castleman disease: report of seven cases and review of theliterature[J]. Eur J Pediatr, 1999, 158(8):631-637.
pmid: 10445341
|
[12] |
Boutboul D, Fadlallah J, Chawki S, et al. Treatment and outcome of unicentric Castleman disease: a retrospective analysis of 71 cases[J]. Br J Haematol, 2019, 186(2):269-273.
|
[13] |
Dong Y, Wang M, Nong L, et al. Clinicalm and laboratory characterization of 114 cases of Castleman disease patients from a single centre:paraneoplastic pemphigus is an unfavourable prognostic factor[J]. Br J Hae Matol, 2015, 169(6):834-842
|
[14] |
Chorzelski T, Hashimoto T, Maciejewska B, et al. Paraneoplastic pemphigus with Castleman tumor, mystasthenia gravis and bronchiolitis obliterans[J]. J Am Acad Dermatol, 1999, 41(3 Pt 1):393-400.
pmid: 10459112
|
[15] |
Wolff H, Kunte C, Messer G, et al. Paraneoplastic pemphigus with fatal pulmonary involvement in a woman with a mesenteric Castleman tumor[J]. Br J Dermatol, 1999, 140(2):313-316.
doi: 10.1046/j.1365-2133.1999.02669.x
|
[16] |
Kim SC, Chang SN, Lee IJ, et al. Localized mucosal involvement and severe pulmonary involvement in a young patient with paraneoplastic pemphigus associated with Castleman’s tumor[J]. Br J Dermatol, 1998, 138:667-671
doi: 10.1046/j.1365-2133.1998.02183.x
|
[17] |
Dispenzieri A. Castleman disease[J]. Cancer Treat Res, 2008, 142:293-330.
pmid: 18283792
|
[18] |
Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 44 published cases[J]. Ann Surg, 2012, 255(4):677-684.
doi: 10.1097/SLA.0b013e318249dcdc
|
[19] |
李卓, 肖娟, 宋红梅, 等. 儿童Castleman病9例临床分析[J]. 中国循证儿科杂志, 2013, 8(4):295-299.
|
[20] |
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease[J]. Blood, 2020, 135(16):1353-1364.
doi: 10.1182/blood.2019000931
pmid: 32106302
|
[21] |
Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti- IL- 6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and castleman disease[J]. Blood, 2008, 112(10):3959-3964
doi: 10.1182/blood-2008-05-155846
pmid: 18784373
|
[22] |
Pribyl K, Vakayil V, Farooqi N, et al. Castleman disease: a single-center case series[J]. Int J Surg Case Rep, 2021, 80:105650.
doi: 10.1016/j.ijscr.2021.105650
|
[23] |
Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinico-pathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease[J]. Am J Hematol, 2016, 91(2):220-226.
doi: 10.1002/ajh.24242
|
[24] |
Van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence based consensus treatment guidelines for idiopathic multicentric castleman disease[J]. Blood, 2018, 132(20):130-138.
doi: 10.1182/blood-2018-99-111413
|
[25] |
Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor[J]. Br J Haematol, 2015, 169(6):834-842.
doi: 10.1111/bjh.2015.169.issue-6
|
[26] |
Leurs A, Gnemmi V, Lionet A, et al. Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review[J]. Front Immunol, 2019, 10:1489.
doi: 10.3389/fimmu.2019.01489
|
[27] |
Miatech JL, Patel NR, Latuso NQ, et al. TAFRO syndrome: a case of significant endocrinopathy in a Caucasian patient[J]. Cureus, 2019, 11(6):e4946
|
[28] |
Takai K, Nikkuni K, Momoi A, et al. Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly: a clinical report of five cases[J]. J Clin Exp Hematop, 2013, 53(1):63-68.
doi: 10.3960/jslrt.53.63
|
[29] |
Dong Y, Zhang L, Nong L, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric castleman disease[J]. Ann Hematol, 2018, 97(9):1641-1647.
doi: 10.1007/s00277-018-3347-0
|
[30] |
吴春波, 张海燕, 邵诗幻, 等. TAFRO综合征六例临床特征及诊疗分析[J]. 中华医学杂志, 2020, 100(8):624-628.
|